380
Participants
Start Date
May 31, 2014
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
KPI-121 0.25%
KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
KPI-121 1.0%
KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Vehicle of KPI-121 0.25%
Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Vehicle of KPI-121 1.0%
Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Raymond Fong, MDPC, New York
Rochester Ophthalmological Group, PC, Rochester
Virginia Eye Consultants, Norfolk
Cornerstone Eye Care, High Point
Westside Research, LLC, Spartanburg
Clayton Eye Center, Morrow
Taustine Eye Center, Louisville
The Eye Center of Columbus, Columbus
Cincinnati Eye Institute, Cincinnati
Price Vision Group, Indianapolis
John-Kenyon American Eye Institute, New Albany
Tekwani Vision Center, St Louis
Ophthalmology Associates, St Louis
Ophthalmology Consultants, St Louis
Tauber Eye Center, Kansas City
The Eye Clinic of Texas, Affiliate of Houston Eye Associates, League City
R&R Eye Research, LLC, San Antonio
Kozlovsky Delay & Winter Eye Consultants, LLC, San Antonio
Las Vegas Physicians Research Group, Henderson
Wolstan & Goldberg Eye Associates, Torrance
Sall Research Medical Center, Artesia
North Valley Eye Medical Group, Mission Hills
Martel Eye Medical Group, Rancho Cordova
Lead Sponsor
Kala Pharmaceuticals, Inc.
INDUSTRY